• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23806 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Multimodal and interdisciplinary interventions for long term pain]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Multigene panel testing for tumors of known origin]
2010     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Multidisciplinary and multisectoral interventions targeting patients with back pain]
2010     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Multidisciplinary and multisectoral interventions targeting patients with back pain – a health technology assessment]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Multicentre study to analyse the effectiveness of telemedicine in spirometry quality assurance programmes]
2012     The Netherlands Organisation for Health Research and Development (ZonMw) [Multicentered randomized controlled trial to test the cost effectiveness of urodynamics in women with symptoms of stress urinary incontinence in whom surgical treatment is considered]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Multi-stage evaluation and revision of information materials on the mammography screening programme]
2008     Andalusian Health Technology Assessment Area (AETSA) [Multi-slice computerised tomography coronary angiography in detecting coronary stenosis. Meta-analysis and economic report]
2006     Andalusian Health Technology Assessment Area (AETSA) [Multi-slice computerised tomography coronary angiography in detecting coronary stenosis. Meta-analysis and economic report]
2008     Andalusian Health Technology Assessment Area (AETSA) [Multi-slice computerised tomography coronary angiography in detecting coronary stenosis. Meta-analysis and economic report.]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [MSCT coronary angiography in patients with stable and unstable angina: a multicenter study]
2011     Haute Autorite de sante (HAS) [MRI-guided vacuum-assisted breast biopsy (VABB)]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [MRI enterography for the assessment of inflammatory bowel disease]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Motorized Intramedullary nails for bone lenghtening in achondroplasia or hypochondropasia]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Motor-driven continuous passive motion (CPM) devices after interventions on the knee and shoulder joint]
2010     Institute for Clinical Effectiveness and Health Policy (IECS) [Motor rehabilitation using ARMEO]
2009     Committee for New Health Technology Assessment (CNHTA) [Motor cortex stimulation]
2011     Norwegian Knowledge Centre for the Health Services (NOKC) [Motivational interviewing for HIV-related behaviors among men who have sex with men]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Motivational interviewing embedded in planned diabetes care for Type 2 patients: effectiveness and efficiency in general practice especially to improve guideline recommendations on diet and exercise]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mosunetuzumab (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [More efficient use of corneal donor donations: the Dutch Lamellar Corneal Transplantation Study (DLCTS-Study)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Montelukast in patients with chronic allergic rhinitis and no asthma]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Monocyte distribution width, MDW]
2013     Andalusian Health Technology Assessment Area (AETSA) [Monoclonal antibodies associated with chemotherapy as first line therapy in metastatic colorectal cancer: relative efficacy, safety and efficiency]
2020     Canary Health Service [Monitoring study: “Endobronchial valves for persistent air leak”]
2021     Canary Health Service [Monitoring study: "The sensor glucose monitoring system (flash-type) for type 1 diabetes mellitus in childhood and adolescence"]
2015     Canary Health Service [Monitoring study protocol (part I): endobronchial valves for persistent air leakage]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Monitoring of stable glaucoma patients: evaluation of the effectiveness and efficiency of a glaucoma follow-up unit, staffed by nonphysician health care professionals, as an intermediate step towards glaucoma monitoring in primary care]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Monitoring of exhaled nitric oxide (FENO) to tailor the lowest effective dose of oral corticosteroids in severe asthma (MONOSA-Study)]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Monitoring depth of anaesthesia - a health technology assessment]
2015     Canary Health Service [Monetary value of a quality-adjusted life year: empirical estimation of the opportunity cost in the national health system]
2014     Canary Health Service [Monetary value of a quality-adjusted life year: a critical review and appraisal of the literature]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Momelotinib (myelofibrosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Health Sciences Institute in Aragon (IACS) [Molecular study of common apoE gene polymorphisms associated with familial dysbetalipoproteinaemia and late-onset Alzheimer’s disease]
2021     Canary Health Service [Molecular markers for the detection of clinically significant prostate cancer]
2011     The Swedish Council on Health Technology Assessment (SBU) [Molecular diagnostic tests for men at higher probability for prostate cancer]
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Molecular characterization of central nervous system tumors by (next-generation sequencing, NGS). Evaluation of diagnostic and prognostic utility and implementation considerations]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mogamulizumab (mycosis fungoides or Sézary syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2015     Haute Autorite de sante (HAS) [Modification of the nomenclature of procedures in laboratory medicine for research into Treponema pallidum (bacteria responsible for syphilis)]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Models of lower back pain: reliability of a classification model]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Models of collaboration and intervention between primary care and mental health in the care of patients diagnosed with depression: results of a meta-review]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Models for providing care and services to patients who have concurrent mental health and substance use disorders]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mobility disorders: does the Feldenkrais method help?]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Mobile cardiopulmonary exercise test in athletes or cardiopulmonary rehabilitation]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Mistletoe therapy with breast cancer]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [Misoprostol for induction of labour]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Misoprostol (induction of labour) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Misoprostol (induction of labour) - Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirvetuximab soravtansin (ovarian cancer) – assessment in accordance with §35a (1) Sentence 11 Social Code Book (SGB) V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Mirabegron for the treatment of storage dysfunction in patients with neurogenic bladder]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirabegron - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2003     Basque Office for Health Technology Assessment (OSTEBA) [Minimum characteristics of a cardiac rehabilitation programme in the Basque Autonomous Community]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mindfulness-based stress reduction: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Migraine surgery]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Miglustat for patients with niemann-pick disease type C]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Miglustat (Zavesca) in the treatment of Niemann-Pick type C disease]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Miglustat (Zavesca) for patients with type 1 Gaucher's disease]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Migalastat for Fabry disease]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) – Addendum to Commission A23-88]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2011     Committee for New Health Technology Assessment (CNHTA) [Microvolt T-wave alternans system]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microvascular reperfusion after percutaneous coronary intervention for acute anterior myocardial infarction - Assessment according to §137h Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microvascular reperfusion after percutaneous coronary intervention for acute anterior myocardial infarction - Addendum to commission H20-01]
2012     Andalusian Health Technology Assessment Area (AETSA) [MicroRNAs as a diagnostic tool for lung cancer]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Microperimetry in retinopathies]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Micrometastases and isolated tumour cells: relevant and robust or rubbish? The MIRROR study in breast cancer]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Microinvasive glaucoma surgery (MIGS) - Hydrus Microstent for the treatment of mild to moderate glaucoma]
2009     Committee for New Health Technology Assessment (CNHTA) [Microdeletion syndrome screening test(MLPA)]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Microdebrider in nose-throat surgeries]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microbial collagenase from Clostridium histolyticum - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mexiletine (myotonia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Metreleptin (lipodystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [Methylnaltrexone for opioid-induced constipation in cancer treatment]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Methods to increase chronically ill patients' participation in health care and services]
2012     The Swedish Council on Health Technology Assessment (SBU) [Methods to estimate and measure renal function (glomerular filtration rate)]
2010     The Swedish Council on Health Technology Assessment (SBU) [Methods of diagnosis and treatment in endodontics - a systematic review of the literature]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Methods for determining the extent of added benefit - empirical data from dossier assessments]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Methods for assessment of innovative medical technologies during early stages of development]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: support for the implementation of a pilot project on the targeted use of medications for the treatment of obesity in designated centers]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: glossary of terms used in pharmacoeconomics]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Methodology report: development and evaluation of a software tool based on GPT-4 to help sort documents for literature reviews - a proof of concept]
2007     Canary Health Service [Methodology for incorporating qualitative studies in health technology assessment]
2019     Basque Office for Health Technology Assessment (OSTEBA) [Methodological project: Synthesis of information in support of multicriteria decision analysis (MCDA) for decision making]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Metformin: Evidence report for the S3 guideline on gestational diabetes mellitus (GDM) – diagnosis, treatment and follow-up care]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Meropenem/vaborbactam (bacterial infections, several therapeutic indications) - Assessment in accordance with § 35a (1c) Social Code Book (SGB) V ]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (hypereosinophilic syndrome) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (hypereosinophilic syndrome) - Addendum to Commission A21-152]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Addendum to Commission A21-151]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Addendum to Commission A21-150]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab - Benefit assessment according to §35a Social Code Book V]